FDA committee to discuss Otsuka's tolvaptan

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Aug. 5 to discuss an NDA from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) for tolvaptan to slow kidney disease in adults with rap...